Effective therapies exist for the treatment of both vaginal trichomoniasis and bacterial vaginosis (BV). Recurrent trichomonas infection is uncommon, and significant metronidazole resistance remains rare. The management of metronidazole-resistant trichomoniasis is dependent on susceptibility studies, which can be used to guide higher doses of metronidazole therapy. Recurrent BV is common. A mechanism for reestablishing the normal vaginal flora with H202-producing lactobacilli 
clinical medicine, accounting for more than 10 3 Treatment failures have been attributed to noncompliance with therapy, reinfection, or in situ inactivation or malabsorption of the drug. [4] [5] [6] Although metronidazole 7 resistance is increasing, it is still uncommon. The 2-g single-dose regimen minimizes noncompliance and is more practical for the treatment of sexual partners. Sexual partners should be treated since reinfection rates of 6.2% to 23 .7% are noted in women whose sexual partners are not treated simultaneously. [6] [7] [8] 
